ITGAE and melanoma: As shown in Table 1, in the past five years, multiple clinical studies indicated that the high level of CD103+ TILs in tumors showed prognostic benefits across multiple types of solid cancer, including cervical cancer, head and neck squamous cell carcinoma, lung and bladder cancer, cholangiocarcinoma, gastric cancer, ovarian cancer, esophageal squamous cell carcinoma, colorectal cancer, and melanoma.